Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells
Authors
Keywords
-
Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 38, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-10-23
DOI
10.1186/s13046-019-1402-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- RER1 enhances carcinogenesis and stemness of pancreatic cancer under hypoxic environment
- (2019) Shi Chen et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Conventionally used reference genes are not outstanding for normalization of gene expression in human cancer research
- (2019) Jihoon Jo et al. BMC BIOINFORMATICS
- Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives
- (2018) Kamil Wdowiak et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling
- (2016) P-F Zhang et al. Cell Death & Disease
- Hypoxia and metabolic adaptation of cancer cells
- (2016) K L Eales et al. Oncogenesis
- The Adverse Effects of Sorafenib in Patients with Advanced Cancers
- (2015) Ye Li et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Galectin-1 is overexpressed in CD133+ human lung adenocarcinoma cells and promotes their growth and invasiveness
- (2015) Xuefeng Zhou et al. Oncotarget
- Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis
- (2014) N M A White et al. BRITISH JOURNAL OF CANCER
- Epidemiology of Hepatocellular Carcinoma
- (2013) Sahil Mittal et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Sorafenib-Induced Hepatocellular Carcinoma Cell Death Depends on Reactive Oxygen Species Production In Vitro and In Vivo
- (2012) R. Coriat et al. MOLECULAR CANCER THERAPEUTICS
- miR-22 represses cancer progression by inducing cellular senescence
- (2011) Dan Xu et al. JOURNAL OF CELL BIOLOGY
- Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation
- (2010) Wei-feng Tan et al. ACTA PHARMACOLOGICA SINICA
- microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity
- (2010) J Zhang et al. BRITISH JOURNAL OF CANCER
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started